Photo from Erman Akkus/X
May 24, 2024, 14:27
First-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman Akkus
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X:
“First-line mFOLFIRINOX for GI high-grade neuroendocrine neoplasms?
- ORR: 77% (complete response: 3%; partial response: 74%)
- mPFS: 12 months
- mOS: 20.6 months
Retrospective, n=35.
Prospective clinical trials are needed, may be considered in patients with high tumor burden and who can tolerate.”
Read further.
Source: Erman Akkus/X